Journey Medical (DERM) Gross Margin (2020 - 2026)

Journey Medical has reported Gross Margin for 7 years, with the latest figure at 60.94% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 260.0% year-over-year to 60.94%; the trailing twelve-month figure through Mar 2026 stood at 65.09% (up 6.0% YoY), and the FY2025 full-year result was 66.17%, up 337.0% from the prior year.
• Gross Margin for Q1 2026 stood at 60.94%, down from 66.17% in the prior quarter.
• The five-year high for Gross Margin was 152.75% in Q4 2023, with the low at 47.2% in Q1 2023.
• Historically, Gross Margin has averaged 65.84% across 5 years, with a median of 60.94% in 2026.
• Annual changes were most pronounced in 2023 — Gross Margin surged 9425 bps — and 2024, when it tumbled 8711 bps.
• Journey Medical's Gross Margin stood at 58.49% in 2022, then soared by 161 bps to 152.75% in 2023, then sank by 57 bps to 65.64% in 2024, then climbed by 1 bps to 66.17% in 2025, then retreated by 8 bps to 60.94% in 2026.
• The last three Gross Margin figures came in at 60.94% (Q1 2026), 66.17% (Q4 2025), and 66.2% (Q3 2025), per Business Quant data.